- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06188689
Évaluation d'un test de diagnostic clinique pour le CRDS (DIAGNOSE CRDS)
Évaluation d'un test de diagnostic clinique pour le syndrome de déficit en libération de calcium : l'étude DIAGNOSE CRDS
Calcium Release Deficiency Syndrome (CRDS) is a novel inherited arrhythmia syndrome secondary to RyR2 loss-of-function that confers a risk of sudden cardiac death. Diagnosis of CRDS presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. We hypothesize that CRDS can be diagnosed clinically through evaluation of the repolarization response to brief tachycardia, mediated by cardiac pacing, and a subsequent pause.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
RyR2 loss-of-function variants have recently been established as causative for a new disease termed calcium release deficiency syndrome (CRDS) that confers a risk of malignant ventricular arrhythmias and sudden cardiac death. RyR2 encodes the cardiac ryanodine receptor, the calcium release channel on the sarcoplasmic reticulum that mediates excitation-contraction coupling through calcium-induced calcium-release. In contrast to CRDS, pathogenic RyR2 gain-of-function variants result in an autosomal dominant form of catecholaminergic polymorphic ventricular tachycardia (CPVT). The adrenergic-mediated ventricular arrhythmias characteristic of CPVT can be readily reproduced on exercise stress testing (EST), making EST the standard clinical diagnostic tool for CPVT.
In contrast to CPVT, the CRDS clinical phenotype is concealed with standard cardiac testing tools and its diagnosis presently requires cellular-based in vitro confirmation that an RyR2 variant causes loss-of-function. Beyond the significant time delay associated with in vitro functional analysis, this testing requires specialized expertise that is not widely available and remains research-based, making it impractical for routine use in clinical care. In this overall context, it is likely that the vast majority of global CRDS cases have yet to be diagnosed.
A prior report of an "atypical CPVT" family carrying an RyR2-p.M4109R variant observed marked and transient repolarization changes following pacing mediated tachycardia and a subsequent pause. Since publication of this report, in vitro characterization of the RyR2-p.M4109R variant has confirmed its being loss-of-function and the familial diagnosis has been revised to CRDS. Driven by these observations and promising preliminary findings, the DIAGNOSE CRDS study seeks to further investigate this apparent electrocardiographic signature of CRDS following brief tachycardia and subsequent pause as a potential method to clinically diagnose the condition.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Jason Roberts, MD MAS
- Numéro de téléphone: 40632 905-297-3479
- E-mail: jason.roberts@phri.ca
Lieux d'étude
-
-
-
Brussels, Belgique, 1090
- Recrutement
- Universitair Ziekenhuis Brussel
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Luigi Pannone, MD
-
-
Antwerp
-
Edegem, Antwerp, Belgique, 2650
- Recrutement
- Antwerp University Hospital
-
Chercheur principal:
- Johan Saenen, MD, PhD
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 1N4
- Recrutement
- University of Calgary
-
Chercheur principal:
- Erkan Ilhan, MD
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Edmonton, Alberta, Canada, T6G 2C8
- Recrutement
- Alberta Health Services
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Joseph Atallah, MD CM, MSc
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z3
- Recrutement
- The University of British Columbia
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Thomas M Roston, MD
-
Vancouver, British Columbia, Canada, V6H 3N1
- Recrutement
- Children's & Women's Health Centre of British Columbia
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Shubhayan Sanatani, MD
-
-
Ontario
-
Hamilton, Ontario, Canada, L8L 2X2
- Recrutement
- Hamilton General Hospital
-
Chercheur principal:
- Jason D Roberts, MD MAS
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
London, Ontario, Canada, N6A 5A5
- Recrutement
- London Health Sciences Centre - University Hospital
-
Chercheur principal:
- Habib R Khan, MD
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Ottawa, Ontario, Canada, K1Y 4W7
- Recrutement
- Ottawa Heart Institute
-
Chercheur principal:
- Simon Hansom, MD
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Toronto, Ontario, Canada, M5G 2C4
- Recrutement
- Toronto General Hospital
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Michael H. Gollob, MD, FRCP(C)
-
-
Quebec
-
Montreal, Quebec, Canada, H1T 1C8
- Recrutement
- Montréal Heart Institute
-
Chercheur principal:
- Rafik Tadros, MD PhD
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Québec, Quebec, Canada, G1V 4G5
- Recrutement
- Institut Universitaire de Cardiologie et de Pneumologie de Québec-Université Laval
-
Chercheur principal:
- Christian Steinberg, MD
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
-
-
-
-
Aarhus, Danemark, DK-8200 N
- Recrutement
- Aarhus University Hospital
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Henrik Jensen, MD
-
-
-
-
New Aquitaine
-
Bordeaux, New Aquitaine, France, 33404
- Recrutement
- CHU de Bordeaux
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Frédéric Sacher, MD
-
-
-
-
-
Jerusalem, Israël, 9103102
- Recrutement
- Shaare Zedek Medical Center
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Ziv Dadon, MD
-
-
-
-
London
-
London, London, Royaume-Uni, WC1N 3JH
- Recrutement
- Great Ormond Street Hospital
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Luke Starling, BSc (Hons), MB BS, FRCPCH
-
-
Oxfordshire
-
Oxford, Oxfordshire, Royaume-Uni, OX3 9DU
- Recrutement
- Oxford University Hospitals
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Julian Ormerod, BM, Bch, FRCP
-
-
-
-
California
-
San Francisco, California, États-Unis, 94143
- Recrutement
- University of California
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Vasanth Vedantham, MD, PhD
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02115
- Recrutement
- Boston Children's Hospital
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Dominic Abrams, MBBS, MD, MBA
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Recrutement
- Mayo Clinic
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- John Giudicessi, MD, PhD
-
-
Washington
-
Seattle, Washington, États-Unis, 98195
- Recrutement
- University of Washington
-
Contact:
- Project Manager
- Numéro de téléphone: 905-521-2100
- E-mail: crds@phri.ca
-
Chercheur principal:
- Uyanga Batnyam, MD
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Cohort 1: Calcium Release Deficiency Syndrome (CRDS) Cases
Inclusion criteria:
• Presence of an RyR2 variant confirmed to be loss-of-function on in vitro testing
Exclusion criteria:
• Unable to provide informed consent
Cohort 2: Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Cases
Inclusion criteria:
- Satisfy a clinical phenotype consistent with the Expert Consensus Statement
- Presence of a confirmed or presumed pathogenic gain-of-function RyR2 variant OR homozygous or compound heterozygous for likely pathogenic/pathogenic CASQ2 variants
Exclusion criteria:
- Unable to provide informed consent
- Use of a QT prolonging medication, aside from flecainide, at the time of the burst pacing maneuvers
Cohort 3: Survivors of Unexplained Cardiac Arrest (UCA)
Inclusion criteria:
- Cardiac arrest requiring cardioversion or defibrillation that remains unexplained following an ECG, echocardiogram, coronary assessment, cardiac MRI, and exercise treadmill test
- Undergone genetic testing that includes screening of RyR2*
Exclusion criteria:
-
Unable to provide informed consent
-
Use of a QT prolonging medication at the time of the burst pacing maneuvers
- Among survivors of UCA that possess a rare RyR2 variant in the absence of a CPVT phenotype, in vitro functional testing will be performed in order to confirm it is not loss- or gain-of-function (and will be arranged through the laboratory of Dr. Wayne Chen at the University of Calgary).
Cohort 4: SVT controls
Inclusion criteria:
• Undergoing an invasive electrophysiology study
Exclusion criteria:
- Ventricular cardiomyopathy
- Ventricular pre-excitation
- Long QT syndrome
- Use of a QT prolonging medication at the time of the EP study
- Use of a Class I or Class III anti-arrhythmic drug at the time of the EP study
- Known obstructive coronary artery disease (existing coronary stenosis >50%)
- Unable to provide informed consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Diagnostique
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Pacing
Separate ventricular and atrial pacing trains will be administered at different cycle lengths and the ventricular repolarization response on the first sinus beat following the subsequent pause will be evaluated. |
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
ΔT-wave amplitude value
Délai: At time of pacing maneuver
|
T-wave amplitude on first post-pause sinus beat subtracted by the T-wave amplitude on the last sinus beat prior to pacing |
At time of pacing maneuver
|
|
ΔQT value
Délai: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat subtracted by the absolute QT value on the last sinus beat prior to pacing |
At time of pacing maneuver
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Absolute QT value
Délai: At time of pacing maneuver
|
Absolute QT value on first post-pause sinus beat |
At time of pacing maneuver
|
|
Absolute T-wave amplitude
Délai: At time of pacing maneuver
|
Absolute T-wave amplitude on first post-pause sinus beat |
At time of pacing maneuver
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Directeur d'études: Ziv Dadon, MD, Shaare Zedek Medical Center
- Chercheur principal: Jason D Roberts, MD MAS, McMaster University
- Chercheur principal: Wayne Chen, PhD, University of Calgary
Publications et liens utiles
Publications générales
- Sun B, Yao J, Ni M, Wei J, Zhong X, Guo W, Zhang L, Wang R, Belke D, Chen YX, Lieve KVV, Broendberg AK, Roston TM, Blankoff I, Kammeraad JA, von Alvensleben JC, Lazarte J, Vallmitjana A, Bohne LJ, Rose RA, Benitez R, Hove-Madsen L, Napolitano C, Hegele RA, Fill M, Sanatani S, Wilde AAM, Roberts JD, Priori SG, Jensen HK, Chen SRW. Cardiac ryanodine receptor calcium release deficiency syndrome. Sci Transl Med. 2021 Feb 3;13(579):eaba7287. doi: 10.1126/scitranslmed.aba7287.
- Nof E, Belhassen B, Arad M, Bhuiyan ZA, Antzelevitch C, Rosso R, Fogelman R, Luria D, El-Ani D, Mannens MM, Viskin S, Eldar M, Wilde AA, Glikson M. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm. 2011 Oct;8(10):1546-52. doi: 10.1016/j.hrthm.2011.05.016. Epub 2011 May 26.
- Ormerod JOM, Ormondroyd E, Li Y, Taylor J, Wei J, Guo W, Wang R, Sarton CNS, McGuire K, Dreau HMP, Taylor JC, Ginks MR, Rajappan K, Chen SRW, Watkins H. Provocation Testing and Therapeutic Response in a Newly Described Channelopathy: RyR2 Calcium Release Deficiency Syndrome. Circ Genom Precis Med. 2022 Feb;15(1):e003589. doi: 10.1161/CIRCGEN.121.003589. Epub 2021 Dec 24.
- Roston TM, Wei J, Guo W, Li Y, Zhong X, Wang R, Estillore JP, Peltenburg PJ, Noguer FRI, Till J, Eckhardt LL, Orland KM, Hamilton R, LaPage MJ, Krahn AD, Tadros R, Vinocur JM, Kallas D, Franciosi S, Roberts JD, Wilde AAM, Jensen HK, Sanatani S, Chen SRW. Clinical and Functional Characterization of Ryanodine Receptor 2 Variants Implicated in Calcium-Release Deficiency Syndrome. JAMA Cardiol. 2022 Jan 1;7(1):84-92. doi: 10.1001/jamacardio.2021.4458.
- Ni M, Dadon Z, Ormerod JOM, Saenen J, Hoeksema WF, Antiperovitch P, Tadros R, Christiansen MK, Steinberg C, Arnaud M, Tian S, Sun B, Estillore JP, Wang R, Khan HR, Roston TM, Mazzanti A, Giudicessi JR, Siontis KC, Alak A, Acosta JG, Divakara Menon SM, Tan NS, van der Werf C, Nazer B, Vivekanantham H, Pandya T, Cunningham J, Gula LJ, Wong JA, Amit G, Scheinman MM, Krahn AD, Ackerman MJ, Priori SG, Gollob MH, Healey JS, Sacher F, Nof E, Glikson M, Wilde AAM, Watkins H, Jensen HK, Postema PG, Belhassen B, Chen SRW, Roberts JD. A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome. JAMA. 2024 Jul 16;332(3):204-213. doi: 10.1001/jama.2024.8599.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 14546
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .